Jiang Hao, Zhao Wei, Shao Wei
Department of Respiratory Medicine, The Second Affiliated Hospital, Southeast University, 1-1 Zhongfu Street, Nanjing, Jiangsu, 210003, People's Republic of China,
Tumour Biol. 2014 Aug;35(8):7383-9. doi: 10.1007/s13277-014-2150-3. Epub 2014 Jun 7.
We sought to clarify the prognostic value of CD44 in survival of patients with non-small cell lung cancer (NSCLC). We performed a meta-analysis of relevant literature to aggregate the available survival results, using studies published in English until March 2014. Eligible studies dealt with CD44, CD44 standard form (CD44s) and CD44 variant 6 (CD44v6), assessment in NSCLC patients on primary lesions and reported survival data according to CD44 and CD44 isoforms expression. We aggregated 10 trials (5 trials for CD44v6, 3 trials for CD44, and 2 trials for CD44s) comprising 1,074 patients, in this meta-analysis. The combined hazard ratio (HR) with CD44v6 and CD44s was 2.39 (95 % confidence interval (CI) 1.69-3.37) and 1.64 (95 % CI 1.06-2.52), respectively. It associated high CD44v6 and CD44s expression with poor survival in NSCLC patients. However, CD44 overexpression did not significantly correlate with survival in patients with NSCLC (HR 1.44; 95 % CI 0.72-2.89). Our meta-analysis shows that CD44v6 and CD44s overexpression indicates poor prognosis for NSCLC patients. However, the high CD44 expression is not significantly correlated with survival for patients with NSCLC.
我们旨在阐明CD44在非小细胞肺癌（NSCLC）患者生存中的预后价值。我们对相关文献进行了荟萃分析，以汇总现有的生存结果，使用的是截至2014年3月以英文发表的研究。符合条件的研究涉及CD44、CD44标准型（CD44s）和CD44变异体6（CD44v6），对NSCLC患者原发性病变进行评估，并根据CD44和CD44亚型表达报告生存数据。在这项荟萃分析中，我们汇总了10项试验（5项针对CD44v6，3项针对CD44，2项针对CD44s），共1074例患者。CD44v6和CD44s的合并风险比（HR）分别为2.39（95%置信区间（CI）1.69 - 3.37）和1.64（95%CI 1.06 - 2.52）。这表明NSCLC患者中CD44v6和CD44s高表达与生存不良相关。然而，CD44过表达与NSCLC患者的生存无显著相关性（HR 1.44；95%CI 0.72 - 2.89）。我们的荟萃分析表明，CD44v6和CD44s过表达提示NSCLC患者预后不良。然而，CD44高表达与NSCLC患者的生存无显著相关性。
